Automated synthesis of [

Automation F-18 PSMA Radiohybrid

Journal

EJNMMI radiopharmacy and chemistry
ISSN: 2365-421X
Titre abrégé: EJNMMI Radiopharm Chem
Pays: England
ID NLM: 101714628

Informations de publication

Date de publication:
23 Jan 2021
Historique:
received: 18 11 2020
accepted: 11 01 2021
entrez: 23 1 2021
pubmed: 24 1 2021
medline: 24 1 2021
Statut: epublish

Résumé

The radiohybrid (rh) prostate-specific membrane antigen (PSMA)-targeted ligand [ [ The automated production of [ This investigation demonstrates that

Identifiants

pubmed: 33484364
doi: 10.1186/s41181-021-00120-5
pii: 10.1186/s41181-021-00120-5
pmc: PMC7826325
doi:

Types de publication

Journal Article

Langues

eng

Pagination

4

Subventions

Organisme : Deutsche Forschungsgesellschaft
ID : SFB 824, B11, Z1
Organisme : Deutsche Forschungsgesellschaft
ID : SFB 824 B11, Z

Références

J Nucl Med. 2010 Mar;51(3):454-61
pubmed: 20150268
J Nucl Med. 2017 May;58(5):687-688
pubmed: 28408526
Bioconjug Chem. 2012 Jan 18;23(1):106-14
pubmed: 22148255
J Urol. 2018 Jan;199(1):126-132
pubmed: 28736318
Bioconjug Chem. 2015 Dec 16;26(12):2350-9
pubmed: 26420336
Nucl Med Biol. 2020 Jul 30;88-89:86-95
pubmed: 32828007
Eur J Nucl Med Mol Imaging. 2017 Apr;44(4):678-688
pubmed: 27889802
EJNMMI Res. 2020 Dec 7;10(1):149
pubmed: 33284394
J Nucl Med. 2015 Jul;56(7):1100-5
pubmed: 25977461
Int J Appl Radiat Isot. 1985 Apr;36(4):318-9
pubmed: 4018894
Angew Chem Int Ed Engl. 2006 Sep 11;45(36):6047-50
pubmed: 16888726
J Nucl Med. 2020 May;61(5):710-715
pubmed: 31836681
Bioconjug Chem. 2015 Jan 21;26(1):1-18
pubmed: 25473848
J Nucl Med. 2020 May;61(5):702-709
pubmed: 31836686
J Nucl Med. 2020 May;61(5):696-701
pubmed: 31836682
Eur J Nucl Med Mol Imaging. 2020 Apr;47(4):870-880
pubmed: 31492994
Bioconjug Chem. 2016 Feb 17;27(2):267-79
pubmed: 26566577
J Nucl Med. 2017 Mar;58(3):425-431
pubmed: 27789722
J Labelled Comp Radiopharm. 2018 May 2;:
pubmed: 29722070
Bioconjug Chem. 2007 Nov-Dec;18(6):2085-9
pubmed: 18030993
J Nucl Med. 2009 Jun;50(6):991-8
pubmed: 19443594
Chem Rev. 2008 May;108(5):1501-16
pubmed: 18426240
Pharmaceuticals (Basel). 2017 Sep 27;10(4):
pubmed: 28953234
J Nucl Med. 2018 Apr;59(4):568-572
pubmed: 29284673
J Am Chem Soc. 2005 Sep 28;127(38):13094-5
pubmed: 16173707
Clin Cancer Res. 2011 Dec 15;17(24):7645-53
pubmed: 22042970
J Nucl Med. 2020 May;61(5):735-742
pubmed: 31862804
J Nucl Med. 2015 Aug;56(8):1169-76
pubmed: 26089548
Biomed Res Int. 2014;2014:454503
pubmed: 25157357
Nuklearmedizin. 2012;51(1):1-8
pubmed: 21989864
Nat Protoc. 2012 Nov;7(11):1946-55
pubmed: 23037309

Auteurs

Alexander Wurzer (A)

Chair of Pharmaceutical Radiochemistry, Technical University of Munich, Walther-Meißner-Str. 3, 85748, Garching, Germany. Alexander.Wurzer@tum.de.

Daniel Di Carlo (D)

Chair of Pharmaceutical Radiochemistry, Technical University of Munich, Walther-Meißner-Str. 3, 85748, Garching, Germany.

Michael Herz (M)

Department of Nuclear Medicine, Klinikum rechts der Isar, Technical University of Munich, Munich, Germany.

Antonia Richter (A)

Department of Nuclear Medicine, Klinikum rechts der Isar, Technical University of Munich, Munich, Germany.

Stephanie Robu (S)

Department of Nuclear Medicine, Klinikum rechts der Isar, Technical University of Munich, Munich, Germany.

Ralf Schirrmacher (R)

Department of Oncology, University of Alberta, Edmonton, Alberta, Canada.

Alba Mascarin (A)

Scintomics GmbH, Fuerstenfeldbruck, Germany.

Wolfgang Weber (W)

Department of Nuclear Medicine, Klinikum rechts der Isar, Technical University of Munich, Munich, Germany.

Matthias Eiber (M)

Department of Nuclear Medicine, Klinikum rechts der Isar, Technical University of Munich, Munich, Germany.

Markus Schwaiger (M)

Department of Nuclear Medicine, Klinikum rechts der Isar, Technical University of Munich, Munich, Germany.

Hans-Juergen Wester (HJ)

Chair of Pharmaceutical Radiochemistry, Technical University of Munich, Walther-Meißner-Str. 3, 85748, Garching, Germany.

Classifications MeSH